Logo image of CCCC

C4 THERAPEUTICS INC (CCCC) Stock Fundamental Analysis

NASDAQ:CCCC - Nasdaq - US12529R1077 - Common Stock

3.685  -0.17 (-4.29%)

Fundamental Rating

4

CCCC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CCCC as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CCCC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CCCC has reported negative net income.
In the past year CCCC has reported a negative cash flow from operations.
In the past 5 years CCCC always reported negative net income.
In the past 5 years CCCC reported 4 times negative operating cash flow.
CCCC Yearly Net Income VS EBIT VS OCF VS FCFCCCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 50M -50M -100M

1.2 Ratios

CCCC has a better Return On Assets (-28.05%) than 70.97% of its industry peers.
CCCC has a Return On Equity of -43.48%. This is in the better half of the industry: CCCC outperforms 70.09% of its industry peers.
Industry RankSector Rank
ROA -28.05%
ROE -43.48%
ROIC N/A
ROA(3y)-27.17%
ROA(5y)-26.81%
ROE(3y)-39.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CCCC Yearly ROA, ROE, ROICCCCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 1K 2K 3K 4K

1.3 Margins

CCCC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CCCC Yearly Profit, Operating, Gross MarginsCCCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -200 -400 -600

More info and screens

7

2. Health

2.1 Basic Checks

CCCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CCCC has been increased compared to 1 year ago.
The number of shares outstanding for CCCC has been increased compared to 5 years ago.
CCCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CCCC Yearly Shares OutstandingCCCC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M
CCCC Yearly Total Debt VS Total AssetsCCCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -1.21, we must say that CCCC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.21, CCCC is in line with its industry, outperforming 56.81% of the companies in the same industry.
CCCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.21
ROIC/WACCN/A
WACC11.27%
CCCC Yearly LT Debt VS Equity VS FCFCCCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 6.31 indicates that CCCC has no problem at all paying its short term obligations.
CCCC's Current ratio of 6.31 is fine compared to the rest of the industry. CCCC outperforms 63.36% of its industry peers.
A Quick Ratio of 6.31 indicates that CCCC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.31, CCCC is in the better half of the industry, outperforming 63.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.31
Quick Ratio 6.31
CCCC Yearly Current Assets VS Current LiabilitesCCCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.00% over the past year.
Looking at the last year, CCCC shows a very strong growth in Revenue. The Revenue has grown by 65.51%.
CCCC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.40% yearly.
EPS 1Y (TTM)37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.69%
Revenue 1Y (TTM)65.51%
Revenue growth 3Y-14.49%
Revenue growth 5Y1.4%
Sales Q2Q%38.75%

3.2 Future

CCCC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.72% yearly.
CCCC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 47.04% yearly.
EPS Next Y41.77%
EPS Next 2Y15.59%
EPS Next 3Y10.56%
EPS Next 5Y18.72%
Revenue Next Year66.46%
Revenue Next 2Y-12.06%
Revenue Next 3Y-6.19%
Revenue Next 5Y47.04%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CCCC Yearly Revenue VS EstimatesCCCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
CCCC Yearly EPS VS EstimatesCCCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20 30 40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CCCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CCCC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CCCC Price Earnings VS Forward Price EarningsCCCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CCCC Per share dataCCCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.59%
EPS Next 3Y10.56%

More info and screens

0

5. Dividend

5.1 Amount

CCCC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

C4 THERAPEUTICS INC

NASDAQ:CCCC (1/22/2025, 2:09:10 PM)

3.685

-0.17 (-4.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)02-20 2025-02-20/amc
Inst Owners86.36%
Inst Owner Change0.01%
Ins Owners2.83%
Ins Owner Change7.13%
Market Cap260.12M
Analysts80
Price Target16.47 (346.95%)
Short Float %14.82%
Short Ratio5.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.56%
Min EPS beat(2)9.7%
Max EPS beat(2)31.42%
EPS beat(4)2
Avg EPS beat(4)6.55%
Min EPS beat(4)-14.38%
Max EPS beat(4)31.42%
EPS beat(8)4
Avg EPS beat(8)6.26%
EPS beat(12)7
Avg EPS beat(12)9.45%
EPS beat(16)11
Avg EPS beat(16)16.28%
Revenue beat(2)2
Avg Revenue beat(2)186.74%
Min Revenue beat(2)146.07%
Max Revenue beat(2)227.41%
Revenue beat(4)3
Avg Revenue beat(4)77.63%
Min Revenue beat(4)-63.22%
Max Revenue beat(4)227.41%
Revenue beat(8)4
Avg Revenue beat(8)31.64%
Revenue beat(12)6
Avg Revenue beat(12)39.55%
Revenue beat(16)10
Avg Revenue beat(16)39.58%
PT rev (1m)10.38%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.14%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)25.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.73
P/FCF N/A
P/OCF N/A
P/B 1.07
P/tB 1.07
EV/EBITDA N/A
EPS(TTM)-1.72
EYN/A
EPS(NY)-1.77
Fwd EYN/A
FCF(TTM)-1.01
FCFYN/A
OCF(TTM)-1.01
OCFYN/A
SpS0.48
BVpS3.44
TBVpS3.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.05%
ROE -43.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.17%
ROA(5y)-26.81%
ROE(3y)-39.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.29%
Cap/Sales 1.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.31
Quick Ratio 6.31
Altman-Z -1.21
F-Score5
WACC11.27%
ROIC/WACCN/A
Cap/Depr(3y)168.05%
Cap/Depr(5y)125.73%
Cap/Sales(3y)9.57%
Cap/Sales(5y)7.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.69%
EPS Next Y41.77%
EPS Next 2Y15.59%
EPS Next 3Y10.56%
EPS Next 5Y18.72%
Revenue 1Y (TTM)65.51%
Revenue growth 3Y-14.49%
Revenue growth 5Y1.4%
Sales Q2Q%38.75%
Revenue Next Year66.46%
Revenue Next 2Y-12.06%
Revenue Next 3Y-6.19%
Revenue Next 5Y47.04%
EBIT growth 1Y16.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.1%
EBIT Next 3Y-6.33%
EBIT Next 5YN/A
FCF growth 1Y32.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.5%
OCF growth 3YN/A
OCF growth 5YN/A